市場調査レポート
商品コード
1469104
炎症性腸疾患 (IBD) 治療薬市場:2024-2034年Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
炎症性腸疾患 (IBD) 治療薬市場:2024-2034年 |
出版日: 2024年04月11日
発行: Visiongain Reports Ltd.
ページ情報: 英文 318 Pages
納期: 即日から翌営業日
|
世界の炎症性腸疾患 (IBD) 治療薬の市場規模は、2034年にかけてCAGR 6.2%で成長すると予測されています。
IBD罹患率の上昇が市場需要を押し上げる:
IBDの世界の罹患率および有病率は、先進国と途上国の間で顕著な差はあるものの、増加傾向にあります。クローン病や潰瘍性大腸炎は、欧米型の食生活や生活習慣に起因する可能性があるため、先進諸国に多く見られます。急速な都市化もIBDを含む自己免疫疾患の増加に寄与しています。欧米は罹患率が安定しているように見えますが、新興諸国では増加しており、これはおそらく欧米化と疾患に対する意識の向上によるものと考えられます。最近の研究では、特に以前は罹患率が低かった地域で罹患率が上昇しています。欧州の罹患率がもっとも高く、北米、アジア/中東がそれに続いています。EFCCA (European Federation of Crohn's and Ulcerative Colitis Associations) によると、2022年には世界で1,000万人のIBD患者がいるとされています。また、CCFA (Crohn's &Colitis Foundation of America) によると、米国では毎年7万人が新たにIBDと診断され、約8万人の子供がIBDに罹患していると推定されています。IBDは約160万人の米国人が罹患していると報告されており、そのほとんどが35歳以前に診断されています。
遺伝的要因も関与していますが、罹患率の変化には環境要因の重要性も指摘されています。社会経済的な変化と西洋的なライフスタイルの普及がこの増加に寄与しています。大腸癌のような腸管外症状や合併症は患者に重大なリスクをもたらし、治療による長期的な影響はまだ解明されていません。消化器内科クリニックは、若年層のIBD患者を管理する課題と、併存疾患を持つ高齢化した患者を管理する課題に直面することになり、慎重な管理戦略が必要となります。
IBD治療薬開発の大きな成功が市場の需要を促進:
これまでIBDの診断率は低く、特に新興諸国が影響を受けていました。先進国でもIBDの診断は難しく、長く正確な診断がなされないままでした。しかし、最近の診断法の改善により患者層が拡大し、その結果、治療に対する需要が高まり、市場収益が増加しています。
当レポートでは、世界の炎症性腸疾患 (IBD) 治療薬の市場を調査し、市場概要、市場成長への影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。
The global Inflammatory Bowel Diseases (IBD) Drugs market is projected to grow at a CAGR 6.2% by 2034
The Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034: This report is essential for prominent enterprises seeking fresh revenue opportunities, aiming to enhance their comprehension of the industry and its inherent dynamics. It provides valuable insights for firms interested in diversifying across various sectors or expanding their current activities into new geographical areas.
Rise in IBD Incidence to Boost the Demand of IBD Drugs Market
The global incidence and prevalence of Inflammatory Bowel Disease (IBD) are increasing, with marked variations between developed and developing nations. Crohn's disease and ulcerative colitis are more common in developed countries, potentially due to Western diets and lifestyle factors. Rapid urbanization has also contributed to the rise in autoimmune diseases, including IBD. While the incidence appears stable in the West, it is increasing in the developing countries, possibly due to Westernization and improved disease awareness. Recent studies show rising incidence rates, especially in regions with previously low rates. Europe has the highest incidence rates, followed by North America and Asia/Middle East. According to EFCCA (European Federation of Crohn's and Ulcerative Colitis Associations) in 2022 there were 10 million people living with IBD worldwide. While according to CCFA ( Crohn's & Colitis Foundation of America), as many as 70,000 new cases of IBD are diagnosed in the United States each year and estimated that approximately 80,000 children in the U.S. are affected with IBD. The IBD has reported to affect almost 1.6 million Americans, most of whom are diagnosed before the age of 35.
Genetic factors play a role, but changing incidence rates emphasize the significance of environmental factors. Socioeconomic shifts and the spread of Western lifestyle contribute to this rise. Extra intestinal manifestations and complications like colon cancer pose significant risks to patients, with long-term implications of treatment are still being understood. Gastroenterology clinics will face challenges managing both younger IBD patients and an aging population with comorbidities, necessitating careful management strategies.
Significant success in IBD Drug Development to Drive the Market Demand
Previously, the diagnosis rate of Inflammatory Bowel Disease (IBD) was low particularly impacting developing countries. Even in developed nations, diagnosing IBD was challenging, leading to prolonged misdiagnoses for many sufferers. However, recent improvements in diagnostics have expanded the patient pool, consequently driving demand for treatments and boosting market revenue.
There has been a rapid surge in randomized clinical trials for Crohn's disease (CD) and ulcerative colitis (UC) treatments, accompanied by detailed epidemiological studies. Despite initial debates, it's now evident that IBD predominantly affects individuals in industrialized nations, with its incidence on the rise. With the advent of newer technologies, there has been a paradigm shift reported in treatment of IBD. Some of the major recent developments include launch and approval of new drugs for instance:
In February 2024, Pfizer Inc. disclosed that the European Commission (EC) has approved marketing authorization for VELSIPITY (etrasimod) within the European Union for the management of moderately to severely active ulcerative colitis (UC) in patients aged 16 and above. This approval extends to individuals who have shown insufficient response, loss of response, or intolerance to conventional therapy or a biological agent.
In March 2024, Celltrion USA has introduced ZYMFENTRA (infliximab-dyyb), a subcutaneous (SC) version of infliximab, marking a significant advancement in treatment options. ZYMFENTRA stands as the sole subcutaneous infliximab approved by the U.S. Food and Drug Administration (FDA) in 2023.
In July 2023, the launch of Yuflyma (adalimumab-aaty) has been announced by Celltrion USA, presenting patients with a high-concentration (100mg/mL) and citrate-free formulation as an alternative option. Yuflyma is approved for the treatment of eight conditions, which encompass rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.
Additionally, Fiberoptic colonoscopy with biopsies and ileocolonoscopy have transformed the diagnosis of both UC and CD globally, particularly in defining disease extent and severity, consequently helping the patients to manage and control IBD.
What Questions Should You Ask before Buying a Market Research Report?
How is the Inflammatory Bowel Diseases Drugs market evolving?
What is driving and restraining the Inflammatory Bowel Diseases Drugs market?
How will each Inflammatory Bowel Diseases Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
How will the market shares for each Inflammatory Bowel Diseases Drugs submarket develop from 2024 to 2034?
What will be the main driver for the overall market from 2024 to 2034?
Will leading Inflammatory Bowel Diseases Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
Who are the leading players and what are their prospects over the forecast period?
What are the Inflammatory Bowel Diseases Drugs projects for these leading companies?
How will the industry evolve during the period between 2024 and 2034? What are the implications of Inflammatory
Bowel Diseases Drugs projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the Inflammatory Bowel Diseases Drugs market?
Where is the Inflammatory Bowel Diseases Drugs market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Inflammatory Bowel Diseases Drugs market today, and over the next 10 years:
Our 318-page report provides 112 tables and 192 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them - NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Inflammatory Bowel Diseases Drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2034 and other analyses reveal commercial prospects
In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
You will find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Inflammatory Bowel Diseases Drugs prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.
Segments Covered in the Report
Indication Outlook
Crohn's Disease
Ulcerative Colitis
Route of Administration Outlook
Oral
Parenteral
Rectal
Distribution Channel Outlook
Hospital Pharmacy
Retail Pharmacy
E-commerce Pharmacy
Others
Drug Class Outlook
TNF-alpha Blockers
Integrin Blockers
Interleukin Inhibitors
JAK Inhibitors
S1Ps Modulators and Others
Drugs Outlook
Cimzia
Entyvio
Humira
Rinvoq
Skyrizi
Remicade
Simponi
Stelara
Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:
North America
U.S.
Canada
Europe
Germany
UK
France
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
MEA
GCC
South Africa
Rest of MEA
The report also includes profiles and for some of the leading companies in the Inflammatory Bowel Diseases Drugs Market, 2024 to 2034, with a focus on this segment of these companies' operations.
Leading companies profiled in the report
AbbVie
Biogen
Celltrion Healthcare Co.,Ltd.
F. Hoffmann-La Roche Ltd
Ferring B.V.
Johnsons & Johnsons
Novartis AG
Pfizer
Takeda Pharmaceutical Company Limited
UCB S.A.
Overall world revenue for Inflammatory Bowel Diseases Drugs Market, 2024 to 2034 in terms of value the market will surpass US$29.09 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Inflammatory Bowel Diseases Drugs Market, 2024 to 2034 report help you?
In summary, our 310+ page report provides you with the following knowledge:
Revenue forecasts to 2034 for Inflammatory Bowel Diseases Drugs Market, 2024 to 2034 Market, with forecasts for drugs, drug class, indication and route of administration each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2034 for five regional and 21 key national markets - See forecasts for the Inflammatory Bowel Diseases Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Inflammatory Bowel Diseases Drugs Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Inflammatory Bowel Diseases Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.